2 results about "Drug nanoparticles" patented technology

The present application relates to a kind of lysosome-based nano drug-loaded particles and its application, belong to the field of biological medicine.The present application will be lysosome membrane as the source of biomimetic membrane to be coated on the surface of drug nano-particle, while keeping the stability of lysosome membrane structure Maximum degree retains its naturally occurring hydrolytic enzyme activity, so that the nano drug-loaded particle can be in situ degradation to tumor tissue extracellular matrix during in vivo delivery, thereby effectively weakening the physical barrier of tumor tissue, significantly enhance the permeability, distribution and cell uptake capacity of nano drug in tumor tissue, and on this basis, improve the conditions for immune cells to enter tumor tissue, ultimately improve the tumor treatment effect.

This application discloses a drug nanoparticle targeting PD-L1, its preparation method, and its application, belonging to the field of oncology drug technology. The drug nanoparticle includes a drug and a carrier loading the drug. The drug is atorvaquinone. The carrier is prepared by coupling a second intermediate product with a first intermediate product. The first intermediate product is obtained by reacting bovine serum albumin with a heterobifunctional cross-linking agent. The second intermediate product is generated by reducing a thiol-modified nucleic acid aptamer, where the nucleic acid aptamer is a PD-L1 aptamer, and the heterobifunctional cross-linking agent is Sulfo-SMCC. This application uses a PD-L1-targeting nucleic acid aptamer coupled with bovine serum albumin to encapsulate atorvaquinone, preparing a novel atorvaquinone nanoparticle-targeted drug. This improves the precise targeting effect of atorvaquinone, overcomes the drawbacks of poor water solubility and high dosage of atorvaquinone, and reduces its systemic toxicity.